Persistent Asset Partners’s Novo Nordisk NVO Stock Holding History

Persistent Asset Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23M	Buy	25,600 +21,915	+595%	+$942K	0.37%	55
2026 Q1	$135K	Buy	+3,685	New	+$175K	0.05%	223
2025 Q4	–	Sell	-5,759	Closed	-$294K	–	422
2025 Q3	$320K	Buy	+5,759	New	+$337K	0.22%	103
2025 Q2	–	Sell	-5,859	Closed	-$399K	–	222
2025 Q1	$407K	Buy	+5,859	New	+$484K	0.34%	66

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Persistent Asset Partners's NVO Position: Q2 2026 in Review

Persistent Asset Partners increased its Novo Nordisk (NVO) stake by 595% in Q2 2026, buying an estimated $942K and bringing the position to 25,600 shares worth $1.23M. The position accounts for 0.37% of the portfolio, ranked #55.

Persistent Asset Partners first reported a position in NVO in Q1 2025 and has held it in 4 quarters since. 1,352 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Persistent Asset Partners held 25,600 shares of Novo Nordisk worth $1.23M as of Q2 2026.
Persistent Asset Partners bought 21,915 Novo Nordisk shares in Q2 2026, an estimated $942K.
Novo Nordisk made up 0.37% of Persistent Asset Partners's portfolio in Q2 2026, its #55 holding.
Persistent Asset Partners first reported a position in Novo Nordisk in Q1 2025 and has held it in 4 quarters since.
1,352 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.